# UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

IN RE: TAXOTERE (DOCETAXEL)	)	MDL No. 16-2740
PRODUCTS LIABILITY	)	
LITIGATION	)	SECTION: "H" (5)
	)	
This document relates to:	)	
Barbara Earnest, 16-17144	)	

#### ORDER AND REASONS

Before the Court are several Motions in Limine: Defendants' First Omnibus Motion in Limine (Doc. 7720); Defendants' Second Omnibus Motion in Limine (Doc. 7657); Defendants' Motion in Limine to Preclude Evidence or Argument Referring to Sanofi as a "French" or "Foreign" Company (Doc. 7662); Plaintiff's Motion in Limine to Preclude Evidence Regarding Sanofi's Corporate Character and Good Acts (Doc. 7643); Plaintiff's Motion in Limine to Preclude Testimony and Argument that Plaintiff's Experts Have Not Publicized/Published or Submitted Their Opinions to the FDA or Any Other Organization (Doc. 7644); Plaintiff's Motion in Limine to Preclude Testimony and Evidence Regarding "Stem Cell" Staining (Doc. 7645); Plaintiff's Motion in Limine to Preclude Testimony and Argument Regarding Plaintiff Counsel Advertisements (Doc. 7646); Plaintiff's Motion in Limine to Preclude Defense Counsel from Commenting on or Discussing Certain Matters in the Presence of the Jury or Potential Jurors by Plaintiff (Doc. 7648); Plaintiff's Motion in Limine to Exclude Evidence of Healthcare Costs and Insurance as a Collateral Source (Doc. 7650); Plaintiff's Motion in Limine to Preclude Testimony and Evidence Regarding Other Individuals' Personal Use of Taxotere and Personal Experience with Cancer (Doc. 7661); and Defendants' Motion in Limine to Preclude Evidence or Argument that the Alleged "High Toxicity" of Taxotere Causes or is Associated with Alopecia (Doc. 7664).

### **BACKGROUND**

Plaintiffs in this multidistrict litigation ("MDL") are suing several pharmaceutical companies that manufactured and/or distributed a chemotherapy drug, Taxotere or docetaxel, that Plaintiffs were administered for the treatment of breast cancer or other forms of cancer. Plaintiffs allege that the drug caused permanent alopecia—in other words, permanent hair loss. Plaintiffs bring claims of failure to warn, negligent misrepresentation, fraudulent misrepresentation, and more. The first bellwether trial of Plaintiff Barbara Earnest ("Plaintiff") is set to begin September 16, 2019.

# **LAW AND ANALYSIS**

The following chart addresses the arguments set forth in each Motion before the Court:

Motion in Limine to Preclude	Doc. No.	Ruling
Evidence or Argument Concerning the Purported Moral or Ethical Duties of Pharmaceutical Drug Manufacturers	7720	Granted. However, this ruling does not limit testimony on the standard of care.
Evidence or Argument Concerning Purported Legal Duties and Conclusions	7720	Deferred due to vagueness.

2

<sup>&</sup>lt;sup>1</sup> Docetaxel is the generic version of Taxotere.

Evidence or Argument Concerning Other Lawsuits, Claims, or Investigations Against Defendants and/or Other Sanofi Entities	7720	Granted in part and denied in part. The Court will allow testimony of other lawsuits, claims, or investigations to the extent they relate to alopecia predating Earnest's treatment.
Evidence or Argument Concerning Complaints and Lawsuits Against Other Manufacturers of Docetaxel	7720	Granted in part. Deferred insofar as it concerns any complaints regarding alopecia that were made to the FDA.
Evidence or Argument Concerning the Presence, Absence, or Identity of Defendants' Corporate Representative at Trial	7720	Granted. Counsel is cautioned, however, not to "vouch" improperly for Sanofi.
Evidence or Argument Concerning Defendants' Executive and/or Employee Compensation	7720	Deferred.
Evidence or Argument Concerning the Cost of Taxotere or Prescription Drug Pricing Generally	7720	Granted. If Plaintiff believes the "door is opened" to this evidence, a conference with the Court should be held.
Evidence or Argument Concerning Defendants' Corporate Finances or Employment Decisions	7720	Deferred.
Evidence or Argument Concerning Expert Opinions that Exceed the Scope of Plaintiff's Experts' Rule 26 Expert Disclosures	7720	Deferred due to vagueness, except to the extent this has already been addressed in the Court's rulings on the parties' <i>Daubert</i> Motions.
Evidence or Argument Concerning Defendants' Corporate Intent, Motives, or State of Mind	7720	Granted in part and denied in part. The Court will allow factual evidence that may go to show intent, motive, or state of mind.

Evidence or Argument Concerning Defendants' Corporate Integrity Agreements, Government Investigations or Settlements, or Any Other Alleged "Bad Acts" Unrelated to Taxotere	7720	Granted, unless the door is opened.
Evidence or Argument Concerning Specific Litigation Conduct	7720	Granted.
Evidence or Argument Concerning Alleged Fraud on the FDA	7720	Deferred due to vagueness. The Court notes that there are no allegations of fraud.
Evidence or Argument Concerning what Treatment Dr. Carinder Would Prescribe to Plaintiff Today	7657	Granted. The Court will only allow testimony as to alternate treatments available at the time of Earnest's treatment.
Evidence or Argument Concerning what Plaintiff Would Have Done differently if She Had Been Given Different Risk Information by her Prescribing Oncologist	7657	Denied. As previously ruled, the jury must decide whether the prescribing decision would have changed; this depends on the oncologist's conversations with Plaintiff and what risks Plaintiff was willing to accept.
Evidence or Argument Concerning Non-Expert Causation Testimony	7657	Deferred due to vagueness.
Evidence or Argument Concerning Plaintiff's Motive and/or Mental State	7657	Granted in part and deferred in part due to vagueness. The Court will allow testimony from others as to their observations of Plaintiff from which the factfinder may infer motive or state of mind.

Evidence or Argument Referring to Sanofi as a "French" or "Foreign" Company	7662	Granted in part and denied in part. The Court will allow testimony establishing that Sanofi is a French corporation. The Court will not allow any improper inference or characterization relating to this fact.
Evidence Regarding Sanofi's Corporate Character and Good Acts	7643	Deferred due to vagueness.
Testimony and Argument that Plaintiff's Experts Have Not Publicized/Published or Submitted Their Opinions to the FDA or Any Other Organization	7644	Denied.
Testimony and Evidence Regarding "Stem Cell" Staining	7645	Dismissed as moot. In ruling on Daubert Motions, the Court has already ruled that Defendants can discuss this staining but cannot reference it as part of "failed study."
Testimony and Argument Regarding Plaintiff Counsel Advertisements	7646	Granted in part and denied in part. The Court will allow such testimony as it relates to Earnest only.
Defense Counsel from Commenting on or Discussing Certain Matters in the Presence of the Jury or Potential Jurors by Plaintiff	7648	Granted in part and denied in part. The parties are precluded from (1) referencing any settlement negotiations; (2) referencing the number of attorneys involved in the litigation; and (3) evoking sympathy due to litigation crisis or pharmaceutical costs. Parties are, however, allowed leeway in cross- examination to elicit bias and to argue that testimony is litigation-driven.
Evidence of Healthcare Costs and Insurance as a Collateral Source	7650	Granted in part and denied in part. The Court will allow questions regarding financing of Plaintiff's experts.

Testimony and Evidence Regarding Other Individuals' Personal Use of Taxotere and Personal Experience with Cancer	7661	Deferred.
Evidence or Argument that the Alleged "High Toxicity" of Taxotere Causes or is Associated with Alopecia	7664	Dismissed as moot. As the Court discussed in ruling on <i>Daubert</i> Motions, Plaintiff cannot introduce testimony that Taxotere is "more toxic" than other chemotherapy drugs. If the door is opened, a conference should be held with the Court.

# **CONCLUSION**

For the foregoing reasons, **IT IS ORDERED** that:

- Defendants' First Omnibus Motion in Limine (Doc. 7720) is GRANTED
   IN PART, DENIED IN PART, and DEFERRED IN PART, as set forth herein;
- Defendants' Second Omnibus Motion in Limine (Doc. 7657) is GRANTED IN PART, DENIED IN PART, and DEFERRED IN PART, as set forth herein;
- Defendants' Motion in Limine to Preclude Evidence or Argument Referring to Sanofi as a "French" or "Foreign" Company (Doc. 7662) is **GRANTED IN PART** and **DENIED IN PART**:
- Plaintiff's Motion in Limine to Preclude Evidence Regarding Sanofi's Corporate Character and Good Acts (Doc. 7643) is **DEFERRED**;
- Plaintiff's Motion in Limine to Preclude Testimony and Argument that Plaintiff's Experts Have Not Publicized/Published or Submitted Their Opinions to the FDA or Any Other Organization (Doc. 7644) is **DENIED**;
- Plaintiff's Motion in Limine to Preclude Testimony and Evidence Regarding "Stem Cell" Staining (Doc. 7645) is **DISMISSED AS MOOT**;

- Plaintiff's Motion in Limine to Preclude Testimony and Argument Regarding Plaintiff Counsel Advertisements (Doc. 7646) is **GRANTED IN PART** and **DENIED IN PART**;
- Plaintiff's Motion in Limine to Preclude Defense Counsel from Commenting on or Discussing Certain Matters in the Presence of the Jury or Potential Jurors by Plaintiff (Doc. 7648) is **GRANTED IN PART** and **DENIED IN PART**;
- Plaintiff's Motion in Limine to Exclude Evidence of Healthcare Costs and Insurance as a Collateral Source (Doc. 7650) is **GRANTED IN PART** and **DENIED IN PART**:
- Plaintiff's Motion in Limine to Preclude Testimony and Evidence Regarding Other Individuals' Personal Use of Taxotere and Personal Experience with Cancer (Doc. 7661) is **DEFERRED**; and
- Defendants' Motion in Limine to Preclude Evidence or Argument that the Alleged "High Toxicity" of Taxotere Causes or is Associated with Alopecia (Doc. 7664) is **DISMISSED AS MOOT**.

New Orleans, Louisiana this 10th day of September, 2019.

UNITED STATES DISTRICT JUDGE